Skip to main content
SpringerLink
Log in

Biliary Cancer: Background and Clinical Evidence

  • Chapter
  • First Online:
Radiation Therapy for Gastrointestinal Cancers

  • 1197 Accesses

Abstract

The management of biliary cancer – specifically, extrahepatic cholangiocarcinoma and gallbladder cancer – is challenging. Surgical resection is the mainstay of therapy, but the complex anatomy of the biliary tree and surrounding structures renders surgery a suboptimal approach as monotherapy. Adjuvant therapies, including chemotherapy and radiation therapy, have been studied retrospectively with mixed results. Emerging prospective data, however, suggests some promise for adjuvant therapy. And for patients with unresectable or metastatic disease, prospective studies have identified systemic therapy combinations with some success. Here we will review the clinical background for extrahepatic cholangiocarcinomas and gallbladder cancers, leading to a summary of the general treatment paradigms while highlighting the rationale for each approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009;15:4240–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bartlett DL, Ramanathan RK, Ben-Josef E. Principles and practice of oncology. In: Rosenberg SA, Lawrence TS, Devita VT, editors. Chapter 85 Cancer of the biliary tree. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 1019–47.

    Google Scholar 

  3. Wan X, Zhang H, Chen C, et al. Clinicopathological features of gallbladder papillary adenocarcinoma. [Internet]. Medicine (Baltimore). 2014 [cited 2016 Apr 21];93:e131. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25501049.

  4. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10:288–91.

    Article  PubMed  Google Scholar 

  5. Hirohashi K, Uenishi T, Kubo S, et al. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. [Internet]. Hepatogastroenterology. 2002 [cited 2016 Apr 21];49:326–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11995443.

  6. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. [Internet]. Int J cancer. 2006 [cited 2016 Apr 21];118:1591–602. Available from:http://www.ncbi.nlm.nih.gov/pubmed/16397865.

  7. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. [Internet]. Clin Epidemiol. 2014 [cited 2016 Apr 21];6:99–109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24634588.

  8. Hsing AW, Gao Y-T, Han T-Q, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. [Internet]. Br J Cancer. 2007 [cited 2016 Apr 21];97:1577–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18000509.

  9. Khan ZS, Livingston EH, Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. [Internet]. Arch Surg. 2011 [cited 2016 Apr 21];146:1143–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22006872.

  10. Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy?. [Internet]. J Gastrointest Surg. 2013 [cited 2016 Apr 21];17:1161–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23423431.

  11. Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. [Internet]. Gut. 1996 [cited 2016 Apr 21];38:610–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8707097.

  12. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. [Internet]. Hepatology. 2000 [cited 2016 Apr 21];31:7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10613720.

  13. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. [Internet]. Semin Liver Dis. 2004 [cited 2016 Apr 21];24:115–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15192785.

  14. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shin H-R, Oh J-K, Lim MK, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. [Internet]. J Korean Med Sci. 2010 [cited 2016 Apr 21];25:1011–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20592891.

  16. Parkin DM, Srivatanakul P, Khlat M, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. [Internet]. Int J cancer. 1991 [cited 2016 Apr 21];48:323–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1645697.

  17. Lee SW, Kim HJ, Park JH, et al. Clinical usefulness of 18F–FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. [Internet]. J Gastroenterol. 2010 [cited 2016 Apr 21];45:560–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20035356.

  18. Groot Koerkamp B, Wiggers JK, Gonen M, et al. Survival after resection of perihilar cholangiocarcinoma-Development and external validation of a prognostic nomogram. Ann Oncol. 2015;26:1930–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. [Internet]. J Am Coll Surg. 2015;221:1041–1049. Available from: http://dx.doi.org/10.1016/j.jamcollsurg.2015.09.005.

  20. Saito H, Noji T, Okamura K, et al. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. [Internet]. Surgery. 2015;159:842–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26683498\nhttp://linkinghub.elsevier.com/retrieve/pii/S0039606015009046.

  21. Hu H-J. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. [Internet]. World J Gastroenterol. 2016;22:2601. Available from: http://www.wjgnet.com/1007-9327/full/v22/i8/2601.htm.

  22. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. [Internet]. J Hepatobiliary Pancreat Sci. 2010 [cited 2016 Apr 24];17:449–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19806294.

  23. Furusawa N, Kobayashi A, Yokoyama T, et al. Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality. [Internet]. World J Surg. 2014 [cited 2016 Apr 24];38:1164–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24305942.

  24. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22.

    Article  CAS  PubMed  Google Scholar 

  25. Singal AG, Rakoski MO, Salgia R, et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010;31:625–33.

    Article  CAS  PubMed  Google Scholar 

  26. Lee BS, Lee SH, Son JH, et al. Prognostic value of CA 19–9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. [Internet]. J Gastroenterol Hepatol. 2015;31:493–500. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26220764.

  27. Lee BS, Lee SH, Son JH, et al. Neutrophil–lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. [Internet]. Cancer Immunol Immunother. 2016;65:141–50. Available from: http://link.springer.com/10.1007/s00262-015-1780-7.

  28. Yang X, Yuan J, Chen J, et al. The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 2014;14:652.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Birnbaum DJ, Viganò L, Ferrero A, et al. Locally advanced gallbladder cancer: which patients benefit from resection?. [Internet]. Eur J Surg Oncol. 2014 [cited 2016 Apr 21];40:1008–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24246608.

  30. Lim H, Seo DW, Park DH, et al. Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients. [Internet]. J Clin Gastroenterol. 2013 [cited 2016 Apr 24];47:443–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23188077.

  31. Koh CY, Demirjian AN, Chen W-P, et al. Validation of Revised American Joint Committee on Cancer Staging for Gallbladder Cancer Based on a Single Institution Experience. [Internet]. Am Surg. 2013;79:1045–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017658/.

  32. D’Hondt M, Lapointe R, Benamira Z, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. [Internet]. Eur J Surg Oncol. 2013;39:548–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23522952.

  33. Ruzzenente A, Fassan M, Conci S, et al. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. [Internet]. Ann Surg Oncol. 2016 [cited 2016 Apr 21];23:1699–707. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26717940.

  34. Hanada K, Itoh M, Fujii K, et al. Original paper TZ ? 53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. 1997;33(7):1136–40.

    Google Scholar 

  35. Wee A, Teh M, Raju G. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol. 1994;47:453–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke–associated cholangiocarcinoma. [Internet]. Nat Genet. 2012;44:690–693. Available from: http://dx.doi.org/10.1038/ng.2273.

  37. Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. [Internet]. J Hematol Oncol. 2015;8:58. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4469402&tool=pmcentrez&rendertype=abstract.

  38. Yukawa M, Fujimori T, Hirayama D, et al. Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. [Internet]. Hum Pathol. 1993 [cited 2016 Apr 21];24:37–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8093356.

  39. Kim HJ, Yoo TW, Park DI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. [Internet]. Ann Oncol. 2007 [cited 2016 Apr 21];18:892–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17322545.

  40. Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. [Internet]. Cancer Res. 2001 [cited 2016 Apr 21];61:6971–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11585718.

  41. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. [Internet]. Science. 2014 [cited 2014 Jul 10];344:641–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24812403.

  42. Kaufman M, Mehrotra B, Limaye S, et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci. 2008;5:285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lee CS, Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. [Internet]. Pathol Res Pract. 1995 [cited 2016 Apr 21];191:1087–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8822109.

  44. Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12:1680–5.

    Article  CAS  PubMed  Google Scholar 

  45. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. [Internet]. Gastroenterology. 2012 [cited 2016 Apr 21];142:1021–31.e15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22178589.

  46. Chung JY, Hong SM, Choi BY, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15:660–7.

    Article  CAS  PubMed  Google Scholar 

  47. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013 3:636–647.

    Google Scholar 

  48. Wehbe H, Henson R, Meng F, et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66:10517–24.

    Article  CAS  PubMed  Google Scholar 

  49. Hong H, Jiang L, Lin Y, et al. TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. [Internet]. BMC Cancer. 2016;16:240. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4799527&tool=pmcentrez&rendertype=abstract.

  50. Kiguchi K, Ruffino L, Kawamoto T, et al. Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. [Internet]. Mol Cancer Ther. 2007;6:1709–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17575102.

  51. Boulter L, Guest R V, Kendall TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest. 2015;125:1269–85.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. [Internet]. Cancer. 2003 [cited 2012 Nov 7];98:1689–700. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14534886.

  53. Barreto SG, Pawar S, Shah S, et al. Patterns of failure and determinants of outcomes following radical Re-resection for incidental gallbladder cancer. World J Surg. 2014;38:484–9.

    Article  PubMed  Google Scholar 

  54. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.

    Article  PubMed  Google Scholar 

  55. Kim TH, Han S-S, Park S-J, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. [Internet]. Int J Radiat Oncol Biol Phys. 2011 [cited 2013 Jan 21];81:e853–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21497455.

  56. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. [Internet]. J Cinical Oncol. 2012 [cited 2013 Feb 3];30:1934–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22529261.

  57. Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. [Internet]. Surg Today. 2005 [cited 2013 Feb 3];35:548–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15976951.

  58. Shinohara ET, Mitra N, Guo M, et al. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. [Internet]. Int J Radiat Oncol Biol Phys. 2009 [cited 2013 Feb 3];74:1191–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19201549.

  59. Gold DG, Miller RC, Haddock MG, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. [Internet]. Int J Radiat Oncol Biol Phys. 2009 [cited 2012 Dec 17];75:150–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19297105.

  60. Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. [Internet]. Ann Surg. 2002 [cited 2016 Apr 28];235:392–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11882761.

  61. Ruys AT, Busch OR, Gouma DJ, et al. Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile?. [Internet]. Ann Surg Oncol. 2011 [cited 2016 Apr 28];18:2647–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21347792.

  62. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. [Internet]. Ann Surg. 2006 [cited 2016 Apr 28];243:364–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16495702.

  63. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. [Internet]. Ann Surg. 2005 [cited 2016 May 18];242:451–8. discussion 458–61, Available from: http://www.ncbi.nlm.nih.gov/pubmed/16135931.

  64. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. [Internet]. Gastroenterology. 2012 [cited 2013 Feb 3];143:88–98.e3. quiz e14, Available from: http://www.ncbi.nlm.nih.gov/pubmed/22504095.

  65. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581–6.

    Article  CAS  PubMed  Google Scholar 

  66. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;4:395–7.

    Google Scholar 

  67. Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) – a randomized, multidisciplinary, multinational phase III trial. [Internet]. BMC Cancer. 2015;15:564. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4520064&tool=pmcentrez&rendertype=abstract.

  68. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. [Internet]. Int J Radiat Oncol Biol Phys. 2006 [cited 2013 Jan 1];66:772–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17011452.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

    Anusha Kalbasi

  2. Department of Radiation Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Edgar Ben-Josef

Authors
  1. Anusha Kalbasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edgar Ben-Josef
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anusha Kalbasi .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Theodore Hong

  2. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Prajnan Das

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kalbasi, A., Ben-Josef, E. (2017). Biliary Cancer: Background and Clinical Evidence. In: Hong, T., Das, P. (eds) Radiation Therapy for Gastrointestinal Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-43115-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43115-4_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43113-0

  • Online ISBN: 978-3-319-43115-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation